Level Bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Level Bio hat ein Gesamteigenkapital von SEK8.0M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK15.7M bzw. SEK7.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 1.96m
Eigenkapital	SEK 4.80m
Gesamtverbindlichkeiten	SEK 9.41m
Gesamtvermögen	SEK 14.20m

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Jun 02

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

Feb 10

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Nov 03

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Aug 18

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Mar 07

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Nov 22

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: LEVBIODie kurzfristigen Aktiva des Unternehmens (SEK10.5M) übersteigen seine kurzfristigen Passiva (SEK7.2M).

Langfristige Verbindlichkeiten: LEVBIODie kurzfristigen Vermögenswerte des Unternehmens (SEK10.5M) übersteigen seine langfristigen Verbindlichkeiten (SEK584.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: LEVBIO ist schuldenfrei.

Schulden abbauen: LEVBIO hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: LEVBIO hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: LEVBIO hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 44.4% pro Jahr abnimmt

Level Bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

First quarter 2024 earnings released

AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)

AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Financial position

AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released

AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)

AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

No independent directors

Third quarter 2022 earnings released

Investor sentiment improved over the past week

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)

No independent directors

First quarter 2022 earnings released

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

New 90-day high: kr1.49

New 90-day high: kr1.44

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: kr0.82

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Market pulls back on stock over the past week

New 90-day low: kr1.09

Market bids up stock over the past week

New 90-day low: kr1.20

New 90-day low - kr1.26

New 90-day low - kr1.35

Xanadu Technologies AB, Tataa Biocenter AB and Active Healthtech Nordic AB acquired a 13.17% stake in AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) from Labkompaniet AB.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen